http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103961715-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ff0f90371d7eadf36f3f9961ff4cf9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55192e3555fe198c97e8bf4bcbc36f8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e7d59480fd80b2fadde3a1806fe0ebf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37160799616c93d1cf4c562421ed8c1d |
| publicationDate | 2014-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103961715-A |
| titleOfInvention | A self-assembled doxorubicin nano drug precursor and its preparation method and application |
| abstract | The invention discloses a self-assembled doxorubicin nano-drug precursor, which uses a hydrophilic polyethylene glycol segment as a carrier, and the self-assembled doxorubicin nano-drug precursor has a structure as shown in formula I : where, chain segment The weight average molecular weight is 2000～20000. The invention also discloses the preparation method and application of the doxorubicin nano-drug precursor, the prepared nano-prodrug has high drug loading capacity and high yield, and is suitable for industrial production. By controlling the molecular weight of the hydrophilic polyethylene glycol segment bonded to the hydrophobic DOX molecule at 2000-20000, the present invention significantly prolongs the blood circulation time of the nano-medicine, improves the tumor-targeting ability of the drug, and is effective in BCap37, KB, MCF-7, MCF-7/DAR, KBv200 and other sensitive and drug-resistant tumor cell lines have shown good anti-tumor activity, especially for clinically difficult drug-resistant tumor cell lines with significant anti-tumor activity. I |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108434457-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107375213-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112618728-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113995850-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113995850-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106139159-A |
| priorityDate | 2014-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467870677 |
Total number of triples: 21.